Table 1 Demographics, ICU characteristics/treatment, respiratory and laboratory parameters at ECMO initiation according to groups (high vs. low anti-Xa)

Demographics

 Age (y)

56.1 (10.95); range 19–77

49.6 (11.48); range 25–67

53.9 (11.50); range 19–77)

 Female gender

19 (20.4%)

27 (56.2%)

46 (32.6%)

 Body mass index (kg/m²)

31.9 (7.8)

31 (5.7)

31.6 (7.1)

Respiratory parameters at ECMO initiation

 Positive end-expiratory pressure (mbar)

14 (3.7)

14.1 (3.9)

14.1 (3.7)

 Plateau pressure (mbar)

31 (4.3)

29.9 (4.8)

30.7 (4.5)

 paCO₂ (kPa)

66.7 (19.3)

68.7 (23.9)

67.4 (20.9)

 pH

7.3 (0.1)

7.3 (0.3)

7.3 (0.2)

ICU characteristics/treatment

 Vasopressor need

72 (77.4%)

33 (68.8%)

105 (74.5%)

 Dose of norepinephrine (mcg/min/kg)

0.17 (0.21)

0.12 (0.19)

0.16 (0.21)

 Renal replacement therapy

19 (20.4%)

5 (10.4%)

24 (17.0%)

 SOFA score

12.2 (3.5)

11.1 (3.1)

11.8 (3.4)

 ICU length of stay (days)

33 (IQR 25–48)

41 (IQR 33–57)

37 (IQR 26–50)

 ECMO runtime (days)

17 (IQR 17–29)

22 (IQR 14–32)

19 (IQR 9–27)

 Dexamethasone treatment

64 (68.8%)

47 (97.9%)

111 (78.7%)

 Tocilizumab treatment

2 (2.2%)

16 (33.3%)

18 (12.8%)

Laboratory parameters at ECMO initiation

 C-reactive protein (mg/L)

212.9 (123.5)

150.8 (136.3)

191.3 (131)

 Ferritin (mcg/L)

1925.5 (1805.5)

1168.0 (1052.2)

1697.5 (1648.2)

 Interleukin 6 (ng/L)

4737.3 (21,973.6)

6159.2 (13,175.1)

5249.8 (19,195.9)

 Leukocytes (G/L)

14.4 (7.4)

13.9 (7.6)

14.3 (7.4)

 Thrombocytes (G/L)

227.6 (111.5)

249.2 (124.7)

235 (116.2)

 D-dimers (mg/L)

35.1 (239)

92 (544)

53.6 (365.5)

 Lactate dehydrogenase (U/L)

544.9 (219.9)

529 (216.8)

539.3 (218.1)

 Lactate (mmol/L)

2.2 (2.3)

2.0 (1.3)

2.1 (2)